Table 2.
Meta-analysis of the association between elevated NLR and clinicopathological parameters
| Association | No. of studies | No. of patients | Pooled HR (95% CI) | Heterogeneity | |
|---|---|---|---|---|---|
| I2 (%) | p-value | ||||
| Ann Arbor stage | 8 | 1525 | 2.121 (1.367–3.293) | 76.9 | < 0.001 |
| IPI | 7 | 1170 | 1.869 (0.881–3.962) | 88.8 | < 0.001 |
| B symptoms | 7 | 1474 | 1.867 (1.034–3.372) | 84.3 | < 0.001 |
| BM involvement | 4 | 1004 | 1.550 (1.148–2.094) | 8.0 | 0.353 |
| ECOG-PS | 8 | 1525 | 2.786 (2.067–3.755) | 0 | 0.673 |
| Extranodal sites | 7 | 1422 | 1.314 (0.809–2.133) | 76.2 | < 0.001 |
| LDH | 8 | 1525 | 2.911 (1.550–5.467) | 88.7 | < 0.001 |
IPI international prognostic index, BM bone marrow, ECOG-PS Cooperative Oncology Group performance status, LDH lactate dehydrogenase